CX 804
Alternative Names: CX-804; VM-804Latest Information Update: 02 Jun 2023
Price :
$50 *
At a glance
- Originator Cartexell
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Lung cancer; Neuroblastoma; Ovarian cancer
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Ovarian cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 22 Sep 2022 Preclinical trials in Lung cancer in South Korea (Parenteral) (Helixmith pipeline, September 2022)
- 21 Sep 2022 Preclinical trials in Neuroblastoma in South Korea (Parenteral) (Cartexell pipeline, September 2022)